Sangamo Therapeutics (SGMOQ) Change in Cash (2010 - 2025)

Sangamo Therapeutics' Change in Cash history runs 16 years deep, the most recent figure standing at -$9.6 million for Q4 2025.

• On a quarterly basis, Change in Cash fell 452.59% year-over-year to -$9.6 million in Q4 2025; TTM through Dec 2025 was -$22.5 million, a 583.81% decrease from a year earlier, with the FY2025 full-year figure at -$22.5 million, down 583.81% from the prior year.
• Change in Cash eased to -$9.6 million in Q4 2025 per SGMOQ's latest filing, from -$9.3 million in the prior quarter.
• Across five years, Change in Cash topped out at $46.9 million in Q2 2021 and bottomed at -$58.6 million in Q1 2022.
• The 5-year median for Change in Cash is -$8.8 million (2021), against an average of -$5.6 million.
• Across the five-year window, Change in Cash tumbled 601.64% in 2022 and soared 225.19% in 2024, its largest moves.
• Year by year, Change in Cash stood at $1.9 million in 2021, then surged by 206.26% to $5.9 million in 2022, then tumbled by 292.54% to -$11.3 million in 2023, then soared by 124.02% to $2.7 million in 2024, then tumbled by 452.59% to -$9.6 million in 2025.
• Per Business Quant, the three latest SGMOQ Change in Cash figures stand at -$9.6 million (Q4 2025), -$9.3 million (Q3 2025), and $13.2 million (Q2 2025).